



NP108, an Antimicrobial Polymer with Activity against Methicillin- and Mupirocin-Resistant *Staphylococcus aureus*

Derry K. Mercer, Laura K. Katvars, Fiona Hewitt,* Daniel W. Smith, Jennifer Robertson, Deborah A. O'Neil

NovaBiotics Ltd., Craibstone, Aberdeen, United Kingdom

ABSTRACT *Staphylococcus aureus* is a clinically significant human pathogen that causes infectious diseases ranging from skin and soft tissue infections (SSTI) and health care-associated infections (HAI) to potentially fatal bacteremia and endocarditis. Nasal carriage of *S. aureus*, especially for persistent carriage, is associated with an increased risk of subsequent infection, particularly nosocomial and surgical site infections (SSI), usually via autoinfection. NP108 is a cationic antimicrobial polymer composed of generally recognized as safe (GRAS) amino acid building blocks. NP108 is broad spectrum and rapidly bactericidal (3-log kill in ≤ 3 h), killing bacteria by membrane disruption and cell lysis. NP108, contrary to many antibiotics, shows equally effective antimicrobial activity against a variety of *S. aureus* ($MIC_{100} = 8$ to 500 mg/liter) and *S. epidermidis* ($MIC_{100} = 4$ to 8 mg/liter) isolates, whether exponentially growing or in stationary phase. NP108 is antimicrobially active under nutrient-limiting conditions similar to those found in the anterior nares ($MIC_{100} = 8$ mg/liter) and kills antibiotic-resilient small colony variants ($MIC_{100} = 32$ mg/liter) and *S. aureus* biofilms (prevention, $MIC_{100} = 1$ to 4 mg/liter; eradication, $MIC_{100} \geq 31.25$ mg/liter). NP108 is active against isolates of *S. aureus* resistant to the current standard-of-care decolonization agent, mupirocin, with no significant increase in the MIC_{100} . NP108 is water soluble and has been formulated into compatible aqueous gel vehicles for human use in which antimicrobial efficacy is retained (2.0% [wt/vol]). NP108 is a potential nonantibiotic antimicrobial alternative to antibiotics for the nasal decolonization of *S. aureus*, with clear advantages in its mechanism of action over the existing gold standard, mupirocin.

KEYWORDS antimicrobial activity, nasal decolonization, *Staphylococcus aureus*

Staphylococcus aureus is a major human pathogen, despite existing as a commensal colonizer of the skin in $\sim 30\%$ of the global population (1–3). *S. aureus* is a leading cause of bacterial health care-associated infections (HAI), including surgical site infections (SSI), pleuropulmonary infections, skin and soft tissue infections (SSTI), and osteomyelitis and device-related infections, as well as potentially fatal infections, including bacteremia, endocarditis, and toxic shock syndrome (1–3). Since the advent of the antibiotic era, *S. aureus* has demonstrated a remarkable ability to adapt and develop resistance to almost all antibiotic classes. Methicillin-resistant *Staphylococcus aureus* (MRSA) is resistant to all available penicillins and other β -lactams (4) and, in some cases, other antibiotic classes, including macrolides and tetracyclines (5). Data for 2015 indicate that 10 to 12% of invasive *S. aureus* isolates in the United Kingdom were MRSA (6), and there were an estimated 59,000 cases of MRSA infection and 9,670 attributable deaths in the United States in 2012 (7).

Approximately one-quarter to one-third of humans are asymptomatic persistent

Received 8 March 2017 Returned for modification 12 May 2017 Accepted 3 June 2017

Accepted manuscript posted online 12 June 2017

Citation Mercer DK, Katvars LK, Hewitt F, Smith DW, Robertson J, O'Neil DA. 2017. NP108, an antimicrobial polymer with activity against methicillin- and mupirocin-resistant *Staphylococcus aureus*. Antimicrob Agents Chemother 61:e00502-17. <https://doi.org/10.1128/AAC.00502-17>.

Copyright © 2017 Mercer et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Derry K. Mercer, derry@novabiotics.co.uk.

* Present address: Fiona Hewitt, Lamellar Biomedical Ltd., Phoenix Crescent, Bellshill, United Kingdom.

nasal carriers of *S. aureus*, whereas a further ~30% are intermittent carriers (8, 9). Nasal carriage of *S. aureus*, especially for persistent carriage, has been positively correlated to an increased risk of subsequent infection, usually via autoinfection (10–12). The World Health Organization recently published 29 (13 preoperative and 16 intra- and postoperative) global recommendations for the prevention of SSI, including nasal decolonization with mupirocin ointment in patients with known nasal carriage of *S. aureus* (13, 14). The frequent overuse of mupirocin has quickly been followed by mupirocin resistance (low and high level) with some outbreaks of mupirocin-resistant MRSA reported (15, 16). Mupirocin resistance rates as high as 81% have been reported and are significantly associated with persistent MRSA carriage, decolonization failure, and early recolonization (17–21).

The emergence of mupirocin resistance and examples of decolonization failure means that alternative *S. aureus* decolonization strategies are actively being sought for both mupirocin nasal decolonization and chlorhexidine gluconate washing (16, 22). The use of the lysine polymer, NP108, represents one such alternative.

Antimicrobial peptides (AMPs) are key components of the innate immune system, with examples of AMPs found in all taxonomic kingdoms (23–26). Most endogenous AMPs are cationic (due to the net charge effect of the arginine and lysine content), amphipathic, contain 10 to 50 amino acids, and target the anionic microbial cell membrane, resulting in cell destabilization, membrane lysis, and death (27–30). Polylysines (modified epsilon forms) have been used as preservatives for a range of dairy and meat products (31, 32). With this precedent for synthetic/modified polylysines and natural, lysine-rich AMPs, we therefore investigated whether simple polymers of natural lysines were active against antibiotic-sensitive and antibiotic-resistant *S. aureus*, including methicillin-susceptible *Staphylococcus aureus* (MSSA), MRSA, and mupirocin-sensitive and -resistant isolates. In this manuscript, we describe the *in vitro* activity of NP108, a lysine polymer selected for development for the nasal decolonization of *S. aureus* (MSSA and MRSA) and the prevention of HAI. NP108 is a broad-spectrum rapidly acting bactericidal compound that kills bacterial cells by membrane disruption and cell lysis through mechanisms aligned with those described for endogenous lysine-rich AMPs (31). Our data also demonstrate that NP108, as a highly water-soluble polymer, can be formulated into compatible delivery vehicles for use in humans (application to the anterior nares) without a loss of antimicrobial efficacy.

RESULTS AND DISCUSSION

Antimicrobial activity of NP108 versus *S. aureus* and *S. epidermidis*. The antimicrobial efficacy of NP108 against a panel of 28 *S. aureus* (8 MRSA and 20 MSSA) isolates and 3 *S. epidermidis* isolates was determined by the broth microdilution procedure (see Table S1 in the supplemental material) (33). NP108 MIC₁₀₀ values for all but two of the isolates tested were in the low milligram per liter range (4 to 64 mg/liter), and for the two less-NP108-sensitive isolates, higher MICs (500 mg/liter for *S. aureus* CB005 and 250 mg/liter for *S. aureus* CB007) were recorded and compared favorably with those of epsilon-polylysine and other AMPs (31). The minimum bactericidal concentrations (MBCs) of NP108 against these *Staphylococcus* species isolates were determined and all were identical to the MIC₁₀₀ or within one dilution of the MIC₁₀₀, indicating that NP108 is bactericidal after 20 h, unlike mupirocin, which is bacteriostatic as MBC values (mg/liter) are significantly higher than MIC values (Table 1) (34).

***In vitro* antimicrobial activity of NP108 against low-level mupirocin-resistant mutants of *S. aureus*.** Mupirocin is a competitive inhibitor of bacterial isoleucyl-tRNA synthetase, thereby blocking bacterial protein and RNA synthesis (16, 35). Mupirocin resistance can be categorized as low level (8 to 256 mg/liter) or high level (\geq 512 mg/liter), and isolates of MSSA and MRSA with both resistance types have been described (36–39). Low-level mupirocin-resistant mutants were generated from two strains of MSSA (*S. aureus* NCTC10788 and *S. aureus* NS05R1) and two strains of MRSA (*S. aureus* DSMZ11729 and *S. aureus* NCTC10442). Antibiotic susceptibility testing (Table 2) demonstrated that the mutants were resistant to mupirocin (MIC₁₀₀ = 8 to 16

TABLE 1 Antimicrobial activity of mupirocin against *Staphylococcus* spp^a

Isolate	Features	Mean MIC ₁₀₀ (mg/liter)	MBC (mg/liter)
<i>S. aureus</i> DSMZ11729	MRSA	0.25	>4.0
<i>S. aureus</i> NCTC10442	MRSA	0.50	>8.0
<i>S. aureus</i> BAA-1717	MRSA	0.50	>8.0
<i>S. aureus</i> ATCC 25923	MSSA	0.25	>8.0
<i>S. aureus</i> NS05R1	MSSA, nasal isolate	1.00	8.0
<i>S. aureus</i> NCTC10788	MSSA	0.25	>4.0
<i>S. aureus</i> NCTC6571	MSSA	0.25	>4.0
<i>S. epidermidis</i> ATCC 12228	MSSE	0.25	>8.0
<i>S. epidermidis</i> V1A	MSSE, nasal isolate	0.50	>8.0

^aThe MIC at which 100% growth was inhibited (MIC₁₀₀) and the minimum bactericidal concentration (MBC) at which all cells were killed by mupirocin were determined by the broth microdilution procedure (55) and as described in reference 33, respectively. Results represent the means from 3 experiments which each contained three technical replicates. MSSA, methicillin-sensitive *S. aureus*; MRSA, methicillin-resistant *S. aureus*; MSSE, methicillin-sensitive *S. epidermidis*.

mg/liter), unlike the isogenic mupirocin-sensitive isolates (MIC₁₀₀ < 1 mg/liter). In all cases, the mupirocin-resistant mutants remained equally sensitive to NP108, and in two cases (*S. aureus* DSMZ11729 and *S. aureus* NS05R1), the NP108 MIC was halved. The NP108 MIC values between isogenic mupirocin-resistant and mupirocin-sensitive strains were not statistically significant (unpaired *t* test [GraphPad Prism 4 for Windows]). This demonstrates that there is no evidence of cross-resistance between low-level mupirocin resistance and NP108 efficacy.

Antimicrobial activity of NP108 against small-colony variants of *S. aureus*.

Small-colony variants (SCV) of *S. aureus* are known to have reduced membrane potential ($\Delta\Psi$) compared with that the wild-type (WT) parental strain (40), and this has been shown to adversely affect aminoglycoside (e.g., gentamicin and tobramycin) antibacterial efficacy, as $\Delta\Psi$ facilitates the uptake of aminoglycoside into bacterial cells (41). A reduced $\Delta\Psi$ is also known to adversely affect the efficacy of selected cationic antimicrobial peptides (42–44), and as NP108 is cationic, it was deemed relevant to determine whether the susceptibility of *S. aureus* SCV to NP108 was affected. In a previous study that examined the susceptibility of *S. aureus* WT and SCV to cationic peptides, SCV were less susceptible to protamine and equally susceptible to magainin and human neutrophil peptide-1, but were more susceptible to dermaseptin (45). *S. aureus* SCV have been isolated from sinonasal biopsy specimens of chronic rhinosinusitis patients (46) and can be internalized by and maintained in a human keratinocyte (HaCaT) cell line *in vitro* (47). Therefore, SCV may be associated with *S. aureus* carriage in the anterior nares. SCV of one strain of MRSA (*S. aureus* DSMZ11729) and one of MSSA (*S. aureus* ATCC 25923) were generated, and their susceptibilities to NP108, mupirocin, and tobramycin were

TABLE 2 Antimicrobial activity of NP108 and mupirocin against *S. aureus* and isogenic low-level mupirocin-resistant mutants^a

Isolate	Mean MIC ₁₀₀ (mg/liter)	
	NP108	Mupirocin ^b
<i>S. aureus</i> DSMZ11729 (MRSA)	32	0.5 (S)
<i>S. aureus</i> DSMZ11729 (MRSA) Mup ^r	16	8 (R)
<i>S. aureus</i> NCTC10442 (MRSA)	32	<1 (S)
<i>S. aureus</i> NCTC10442 (MRSA) Mup ^r	32	16 (R)
<i>S. aureus</i> NCTC10788 (MSSA)	8	0.25 (S)
<i>S. aureus</i> NCTC10788 (MSSA) Mup ^r	8	>8 (R)
<i>S. aureus</i> NS05R1 (MSSA)	16	<1 (S)
<i>S. aureus</i> NS05R1 (MSSA) Mup ^r	8	16 (R)

^aThe MIC at which 100% growth was inhibited (MIC₁₀₀) was determined by the broth microdilution procedure (33). Results represent the means from 3 experiments which each contained three technical replicates. Mupirocin susceptibility, MIC ≤ 4 mg/liter; low-level mupirocin resistance, MIC = 8 to 64 mg/liter; high-level mupirocin resistance, MIC ≥ 512 mg/liter (35); MSSA, methicillin-sensitive *S. aureus*; MRSA, methicillin-resistant *S. aureus*; Mup^r, mupirocin resistant.

^bR, resistant; S, sensitive.

TABLE 3 Antimicrobial activity of NP108, mupirocin, and tobramycin against wild-type and SCV of *S. aureus*^a

Isolate	Mean MIC ₁₀₀ (mg/liter)		
	NP108	Tobramycin	Mupirocin
<i>S. aureus</i> DSMZ11729 (MRSA) WT	32	16	0.5
<i>S. aureus</i> DSMZ11729 (MRSA) SCV	64	>256	0.5
<i>S. aureus</i> ATCC25923 (MSSA) WT	32	0.5	0.5
<i>S. aureus</i> ATCC25923 (MSSA) SCV	32	>8	0.5

^aThe MIC at which 100% growth was inhibited (MIC₁₀₀) was determined by the broth microdilution procedure (33). Results represent the means from 3 experiments which each contained three technical replicates. SCV, small-colony variant; WT, wild type. One-way ANOVA was conducted using GraphPad Prism 4 for Windows.

determined (Table 3). The MIC₁₀₀ values of NP108 against *S. aureus* ATCC 25923 WT and SCV were identical (32 mg/liter), whereas the MIC₁₀₀ of *S. aureus* DSMZ11729 SCV was one dilution higher than the MIC₁₀₀ of the WT (64 and 32 mg/liter, respectively) (Table 2), indicating that SCV status has little or no effect on NP108 antibacterial efficacy against these isolates. The MICs of mupirocin were identical for both strains of *S. aureus*, whether WT or SCV (0.5 mg/liter). As expected, the susceptibilities of the SCV to the aminoglycoside antibiotic tobramycin were reduced, with >16-fold increases in MICs for *S. aureus* DSMZ11729 (tobramycin resistant and known to be gentamicin resistant [>50 mg/liter]) (48) and *S. aureus* ATCC 25923 SCV (Table 3). The data were analyzed by one-way analysis of variance (ANOVA), and the differences in antimicrobial susceptibility between the WT and SCV were not statistically significant ($P > 0.05$). Interestingly, *S. aureus* ATCC 25923 WT was tobramycin sensitive (MIC₁₀₀ = 0.5 mg/liter), whereas *S. aureus* ATCC 25923 SCV was of intermediate sensitivity to tobramycin and potentially resistant (MIC₁₀₀ > 8 mg/liter). Despite the fact that *S. aureus* DSMZ11729 was tobramycin resistant (MIC₁₀₀ = 16 mg/liter), there was still an increase in tobramycin MIC (>16-fold) in the SCV isolate (MIC₁₀₀ > 256 mg/liter).

Antimicrobial activity of NP108 versus *S. aureus* under low-nutrient conditions.

The anterior nares are a relatively nutrient-poor environment (49); therefore, for any antimicrobial intended for application for nasal decolonization, it is essential that antimicrobial activity is not compromised under nutrient-limiting conditions in which bacteria are not multiplying or are multiplying slowly. Many antibiotics are not as efficacious under these conditions (50) and therefore may not be suitable for nasal decolonization; but, membrane-active compounds may not be subject to such limitations (51). NP108 was more effective under low-nutrient conditions than under high-nutrient conditions, with the MIC₁₀₀ reduced by 3-fold under low-nutrient conditions for both strains of *S. aureus* (Table 4). Antimicrobial susceptibility differences under low- and high-nutrient conditions were analyzed by one-way ANOVA. The differences between NP108 MICs under low- and high-nutrient conditions were statistically significant ($P < 0.001$), whereas they were not statistically significant for mupirocin ($P > 0.05$). Mupirocin was not adversely affected by low-nutrient conditions, with the MIC₁₀₀

TABLE 4 Antimicrobial activity of NP108 and mupirocin against *S. aureus* DSMZ11729 and *S. aureus* ATCC 25923 under high- and low-nutrient conditions^a

Isolate	Mean MIC ₁₀₀ (mg/liter)			
	NP108		Mupirocin	
	High nutrient	Low nutrient	High nutrient	Low nutrient
<i>S. aureus</i> DSMZ11729	32	8	0.5	0.125
<i>S. aureus</i> ATCC 25923	32	8	0.5	0.5

^aAntimicrobial susceptibility testing was conducted by the broth microdilution procedure (33). High-nutrient condition testing was carried out in 1× CA-MH broth and low-nutrient condition testing was carried out in 0.1× CA-MH broth. Results represent the means from 3 experiments which each contained three technical replicates. One-way ANOVA was conducted using GraphPad Prism 4 for Windows.

reduced by 4-fold in the case of *S. aureus* DSMZ11729 and being unaffected in the case of *S. aureus* ATCC 25923.


Kinetics of NP108 killing of exponential- and stationary-phase *S. aureus*. Most bactericidal antimicrobials require bacteria that are actively growing/metabolizing to produce killing, whereas stationary-phase cultures of *S. aureus* demonstrate significant tolerance to many antibiotics (52, 53). Therefore, the antimicrobial activity of NP108 against exponential-phase and stationary-phase *S. aureus* DSMZ11729, *S. aureus* ATCC 25923, *S. aureus* NCTC10442 mupirocin-sensitive (Mup^s), and *S. aureus* NCTC10442 mupirocin-resistant (Mup^r) isolates was determined. The kinetics of NP108 (4× MIC) for killing 4 isolates of *S. aureus* were such that a 3-log kill was achieved within 3 h of incubation with an inoculum of ~10⁸ CFU/ml of cells (Fig. 1). Stationary-phase cultures were killed as quickly as exponential-phase cultures. When the isogenic mupirocin-resistant isolate of *S. aureus* NCTC10442 was tested, it was killed more rapidly than the mupirocin-sensitive isolate, demonstrating that there was no evidence of cross-resistance with mupirocin and NP108. The 10⁸ CFU/ml represents ~150-fold more cells than are used in broth microdilution antimicrobial susceptibility testing (33) but with only 4-fold more NP108 used. When 4× MBC mupirocin was used against 3 of the isolates (*S. aureus* DSMZ11729, *S. aureus* ATCC 25923, and *S. aureus* NCTC10442), no killing was achieved even after 24 h of incubation (data not shown), which correlates with the slow killing time of mupirocin even at high concentrations (34). It was not possible to test *S. aureus* NCTC10442 Mup^r with 4× MBC of mupirocin, as the mupirocin MBC (>1,024 mg/liter) of this isolate could not be determined due to limits of the aqueous solubility of mupirocin.

Importance of cationicity for the bactericidal mechanism of action of NP108. NP108 is a cationic polylysine polymer (molecular weight [MW], ~22), and the net positive charge is thought to be essential for the membrane-acting bactericidal activity of the compound. To test this hypothesis, the polyanionic compound polyanethole-sulfonic acid (PASA) was included in the MIC assays along with NP108 and the antimicrobial efficacy was determined against *S. aureus* SMRSA105 and *S. aureus* EMRSA16 (Fig. 2). The addition of PASA to NP108 eliminated the antibacterial activity of NP108, while PASA had no effect on *S. aureus* survival alone. In the absence of PASA, NP108 rapidly killed both strains of *S. aureus*, indicating that the cationic properties of NP108 are essential for antimicrobial activity.

Electron microscopy to determine the effect of NP108 on the cellular morphology of *S. aureus*. NP108 has charge-dependent potent bactericidal effects within 1 h, as demonstrated in Fig. 2. Scanning and transmission electron microscopy (SEM and TEM, respectively) were used to investigate the effect of NP108 on the morphology of *S. aureus* SMRSA105. SEM analysis of a 60-min treatment with 60 mg/liter NP108 revealed extensive cellular debris with few intact cells (Fig. 3C). The TEM micrographs (Fig. 3D) revealed that, despite appearing intact, the remaining cells following incubation with 62.5 mg/liter NP108 no longer contained any internal architecture, unlike in the untreated control (Fig. 3B). There is also evidence of buckling and bulging of the cell walls in the treated samples, indicative of a loss of cell integrity and lysis, confirming the rapid bactericidal action of NP108 targeting the cell surface.

Activity of NP108 against *S. aureus* biofilms. The antibiofilm activity of NP108 against established biofilms of *S. aureus* ATCC 25923 (MSSA) and *S. aureus* DSMZ11729 (MRSA) and whether NP108 could prevent biofilm formation by either strain were assessed (Fig. 4). NP108 disrupted *S. aureus* biofilms in a concentration-dependent manner from 31.25 to 500 mg/liter. Interestingly, biofilm prevention was achieved at lower concentrations (4 to 8 mg/liter) for both strains, which are concentrations lower than the MIC₁₀₀ of NP108 against planktonic cells of either strain (32 mg/liter) (Table S1).

Antimicrobial activity of NP108 prepared as water-soluble formulations. NP108 has a high aqueous solubility (>400 g/liter), and so to generate a pharmaceutical formulation suitable for the application of NP108 to the anterior nares, the develop-



Time for 3 log kill (h)

Exponential Phase Stationary Phase

<i>S. aureus</i> DSMZ11729 (MRSA)	2 - 3	1 - 2
<i>S. aureus</i> ATCC25923 (MSSA)	2	1
<i>S. aureus</i> NCTC10442 (MRSA)	1 - 2	2 - 3
<i>S. aureus</i> NCTC10442 (MRSA) MupR	1	1

FIG 1 Effect of NP108 on the survival of *S. aureus* DSMZ11729 (MRSA), *S. aureus* ATCC 25923 (MSSA), *S. aureus* NCTC10442 (MRSA), and *S. aureus* NCTC10442 MupR^r (low-level mupirocin-resistant MRSA) over 6 h of incubation. NP108 was added at 4× MIC to exponential-phase or stationary-phase cultures of the *S. aureus* isolates diluted to the 0.5 McFarland standard (~10⁸ CFU/ml) at 37°C in CA-MH broth (exponential phase) or conditioned CA-MH broth (stationary phase). Samples were taken every 60 min and viable counts established by plating on CA-MH agar and incubating for 24 h at 37°C. Untreated cultures were used as growth controls. Values in the table represent the time taken to kill the isolates of three replicates from 3 independent experiments. The graphs show representative data from a single experiment with each isolate. Data points represent the mean numbers of CFU/ml within the experiment. Horizontal dotted lines represent 3-log reduction in CFU/ml (complete kill). Conditioned CA-MH broth was medium derived from cultures of the relevant *S. aureus* isolate grown to stationary phase (48 to 54 h), and cells were removed by centrifugation (5 min at 17,000 × g) and filter sterilized (0.22-μm PES filter).

ment of an aqueous formulation containing NP108 was a logical choice. This choice of formulation was based on the characteristics required for nasal application, including the retention of antimicrobial activity, the release of the antimicrobial from the formulation, the ease of application, appropriate hydrophilicity, a lack of irritation, and appropriate viscosity/rheological properties. NP108 retained antimicrobial activity against *S. aureus* ATCC 25923 (see Fig. S1B, D, F, H, and J) and other *S. aureus* isolates




FIG 2 The effect of PASA on the antibacterial activity of NP108 against *S. aureus* MRSA. The influence of 2% (wt/vol) PASA in MH broth on the antibacterial efficacy of 62.5 mg/liter NP108 when incubated with *S. aureus* SMRSA105 (A) or *S. aureus* EMRSA16 (B) for 60 min at 37°C (*n* = 9). Data depict the mean numbers of CFU/ml.

(data not shown), whereas none of the base formulations not containing NP108 demonstrated any antimicrobial activity (Fig. S1A, C, E, G, and I). Mupirocin (Bactroban nasal ointment) was also active under the same experimental conditions (Fig. S1K). Thus, NP108 can be included in suitable pharmaceutical formulations for use in subsequent human studies.

Our results from these studies describe the *in vitro* activity and development thus far of NP108, a novel antimicrobial lysine polymer composed of generally recognized as




FIG 3 Electron micrographs demonstrating the effect of NP108 on *S. aureus* SMRSA105. (A) SEM, untreated; (B) TEM, untreated; (C) SEM, 62.5 mg/liter NP108 for 60 min; (D) TEM, 62.5 mg/liter NP108 for 60 min. Bars = 200 nm (A and C) and 100 nm (B and D).




FIG 4 Effect of NP108 on prevention of biofilm formation by *S. aureus* DSMZ11729 (A) and *S. aureus* ATCC 25923 (B) under low-nutrient conditions simulating the anterior nares. Exponentially growing *S. aureus* isolates were diluted to the 0.5 McFarland standard in $0.1\times$ TSB supplemented with 0.05% (wt/vol) glucose, 0.3% (wt/vol) NaCl, and 0 to 16 mg/liter NP108. Biofilms were allowed to establish statically for 96 h at 37°C before biomass formation was assessed by the crystal violet method. Data sets represent the means from triplicate experiments and error bars represent the standard errors of the means. Dotted lines represent the limit of detection. Effect of NP108 on established biofilms of *S. aureus* DSMZ11729 (C) and *S. aureus* ATCC 25923 (D) under low-nutrient conditions simulating the anterior nares. *S. aureus* biofilms were prepared in $0.1\times$ TSB supplemented with 0.05% (wt/vol) glucose and 0.3% (wt/vol) NaCl and allowed to establish statically for 96 h at 37°C. Subsequently, biofilms were treated with different concentrations of NP108 in $0.1\times$ TSB supplemented with 0.05% (wt/vol) glucose and 0.3% (wt/vol) NaCl for a further 24 h at 37°C before biofilm biomass eradication was assessed by the crystal violet method. Data points represent the mean optical densities (at 595 nm) from single experiments and error bars represent the standard errors of the means.

safe (GRAS) amino acid building blocks, for the nasal decolonization of *S. aureus* (MSSA and MRSA) and prevention of HAI. NP108 is rapidly bactericidal (99.9% kill within 3 h of exposure at $4\times$ MIC against $\sim 10^8$ CFU/ml *S. aureus*) in the mg/liter concentration range against *S. aureus* and *S. epidermidis* and acts via charge-dependent membrane disruption, resulting in rapid cell lysis. NP108 shows *in vitro* activity against a variety of *S. aureus* and *S. epidermidis* strains, including nasal isolates, and is equally effective against exponentially growing or stationary-phase *S. aureus* and under nutrient-poor conditions similar to those found in the anterior nares (49). NP108 is effective against antibiotic-resilient small colony variants (SCV) and *S. aureus* biofilms. NP108 is also effective against mupirocin-resistant isolates of *S. aureus*. NP108 is water soluble and has been formulated into compatible vehicles for use in humans without a loss of antimicrobial efficacy. Subsequent studies will evaluate the *in vivo* efficacy of NP108 for *S. aureus* nasal decolonization. There is a clear need for a viable and superior alternative to mupirocin due to the increasing incidence of resistance to/treatment failure by this antibiotic. For example, NP108 has the potential to be superior due to its rapid bactericidal activity, which should significantly reduce the potential for resistance development compared with that of the existing relatively slow-acting bacteriostatic agent mupirocin, the current “gold standard” therapy. In addition, the data presented

here show additional advantages for the use of a lysine polymer as a topical antimicrobial on the basis of the similarities of features to endogenous AMP and on the facts that NP108 is based on GRAS building blocks (GRAS notice 414) and is biodegradable without cytotoxicity and that ϵ -poly-L-lysines have a long history of safe and effective use as antimicrobials in the food industry (GRAS notices 135 and 336) (54). On the basis of the *in vitro* activity data and the potential ease of formulation determined in this study, NP108 will be taken further into preclinical/clinical development for the nasal decolonization of *S. aureus* and the prevention of SSI.

MATERIALS AND METHODS

Growth conditions and reagents. All growth media and chemicals were purchased from Sigma-Aldrich (UK) unless otherwise stated. *S. aureus* DSMZ11729 (ATCC 33592) was obtained from the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (Germany). *S. aureus* ATCC 25923, *S. aureus* BAA-1717, *S. epidermidis* ATCC 35984, and *S. epidermidis* ATCC 12228 were obtained from the American Type Culture Collection (LGC Standards, UK). *S. aureus* NCTC10442, *S. aureus* NCTC10788 (ATCC 6538), and *S. aureus* NCTC6571 (ATCC 9144) were obtained from the National Collection of Type Cultures (Public Health England, UK). *S. aureus* SMRSA105, *S. aureus* SMRSA124, *S. aureus* SMRSA161, *S. aureus* EMRSA16, *S. aureus* MRSA8, *S. aureus* MRSA10, *S. aureus* MSSA1, *S. aureus* MSSA2, *S. aureus* MSSA6, and *S. aureus* MSSA8 were all isolated from dermal wounds and were generous gifts from Gail Ferguson and Isabel Cook of the Medical Microbiology Department, Aberdeen Royal Infirmary (UK). All other isolates were from the anterior nares of healthy volunteers.

Isolation and characterization of nasal *S. aureus*. *Staphylococcus aureus* was isolated from the noses of healthy volunteers using the protocol described in Investigation of nasal samples, a standard for microbiology investigations by the Public Health England, UK (55) after obtaining written informed consent. After their growth, colonies were assessed macroscopically on mannitol salt phenol red (MSPR) agar for growth and mannitol fermentation, and colonies were examined microscopically following Gram staining. Samples were further confirmed as *S. aureus* by the detection of coagulase activity and the presence of protein A in the cell wall (Staphylo Monotec test kit Plus; Sigma-Aldrich, UK). Samples were stored at -85°C in cation-adjusted Mueller-Hinton ([CA-MH] Mueller-Hinton broth 2; Sigma-Aldrich, UK) broth containing 30% (vol/vol) glycerol until required.

Antimicrobial susceptibility testing. The MICs of NP108 and antibiotics (vancomycin, fusidic acid [Discovery Fine Chemicals Ltd., UK], mupirocin [VWR, UK], and tobramycin [Discovery Fine Chemicals Ltd., UK]) were determined by the broth microdilution procedure (33). The MBCs of NP108 and antibiotics were measured following MIC determination using a 96-well replicator (Thermo Fisher Scientific). Briefly, after 20 h of incubation to determine the MICs, a 96-well replicator was used to transfer samples in triplicates from each well to 140-mm petri dishes containing CA-MH agar (no antimicrobials), which were incubated at 37°C until good growth was observed for positive (growth) control colonies (56). The MBC was determined as the lowest concentration of antimicrobial at which no growth was observed. Antimicrobial susceptibility testing was also carried out on *S. aureus* growing under low-nutrient conditions by the broth microdilution procedure (33), except that bacteria were grown in $0.1\times$ CA-MH broth (one-tenth concentration) rather than normal concentration CA-MH broth.

Generation of low-level mupirocin-resistant isolates. Low-level mupirocin-resistant mutants ($\text{MIC}_{100} = 8$ to 64 mg/liter) were generated by exposing a 0.5 McFarland standard inoculum of mupirocin-sensitive isolates of *S. aureus* to doubling concentrations of mupirocin in CA-MH broth every 48 h for up to 16 d with incubation at 37°C , starting at a mupirocin concentration of 0.125 mg/liter on which all strains were able to grow. Mupirocin-resistant isolates were confirmed as *S. aureus* by growth on MSPR agar, macroscopic and microscopic appearance, the detection of coagulase activity, and the presence of protein A in the cell wall. Mupirocin MICs were determined by the broth microdilution procedure (33).

Generation of small-colony variants. Small-colony variants (SCV) of *S. aureus* ATCC 25923 (MSSA) and *S. aureus* DSMZ11729 (MRSA) were generated using the method described by Hoffman and coworkers (57) and characterized as described by Proctor and coworkers (40). SCV and controls were confirmed as *S. aureus* by growth on MSPR agar and their macroscopic and microscopic appearance. Antimicrobial susceptibility testing of SCV for NP018, mupirocin, and tobramycin was performed using the broth microdilution procedure (33). To maintain the SCV phenotype, 10 mg/liter 2-heptyl-4-hydroxyquinoline *N*-oxide (HQNO) was added to SCV cultures to prevent reversion to the wild-type phenotype, and SCV cultures were incubated until good growth was obtained in the untreated SCV controls (48 to 72 h) to compensate for the low growth rate of SCV.

Generation of *S. aureus* biofilms and biofilm eradication. Biofilms of *S. aureus* ATCC 25923 (MSSA) and *S. aureus* DSMZ11729 (MRSA) were generated using the microtiter plate biofilm assay procedure described by Cassat and coworkers (58) with the following modifications. The *S. aureus* culture was resuspended to the 0.5 McFarland standard in $0.1\times$ tryptic soy broth ([TSB] 1:10 dilution of normal concentration TSB) supplemented with 0.05% (wt/vol) glucose and 0.3% (wt/vol) NaCl, and $200\ \mu\text{l}$ was added to each well following the aspiration of plasma. Biofilms were established and treated in lower concentrations of growth medium to simulate the nutrient-poor conditions of the anterior nares (49). Plates were incubated statically at 37°C for 96 h to allow the biofilms to establish. For biofilm eradication studies, planktonic bacteria were removed from the wells after 96 h by gentle aspiration, and all wells were washed 3 times with sterile phosphate-buffered saline ([PBS] Thermo Fisher Scientific Ltd., UK).

Antimicrobials (NP108 or mupirocin) dissolved in $0.1\times$ TSB supplemented with 0.05% (wt/vol) glucose and 0.3% (wt/vol) NaCl were added to the relevant wells and incubated at 37°C for 24 h. Following treatment, biofilms were visualized by staining with crystal violet (59) to determine the amount of biofilm that had been eradicated relative to untreated control wells.

Kinetics of NP108 bactericidal activity. To determine the time that NP108 took to kill *S. aureus*, four isolates were assessed: *S. aureus* DSMZ11729 (MRSA), *S. aureus* ATCC 25923 (MSSA), *S. aureus* NCTC10442 (MRSA), and *S. aureus* NCTC10442 Mup^r (low-level mupirocin-resistant MRSA). *S. aureus* NCTC10442 Mup^r was generated at an earlier stage in this study (see above). For determination of the killing kinetics of exponentially growing *S. aureus*, cultures were diluted to the 0.5 McFarland standard, and 100 μ l was inoculated into 10 ml CA-MH broth and grown overnight (16 to 18 h) at 37°C without shaking. For determination of the killing kinetics of stationary-phase *S. aureus* cultures, isolates were grown as described above but for 48 h. These time points had been previously determined to represent cultures in the exponential or stationary phase in preliminary experiments (data not shown). For exponentially growing cultures, samples of *S. aureus* were diluted to the 0.5 McFarland standard in CA-MH broth (prewarmed to 37°C) before exposure to NP108. For stationary-phase cultures, samples of *S. aureus* were diluted to the 0.5 McFarland standard in conditioned CA-MH broth (prewarmed to 37°C) before exposure to NP108. Conditioned CA-MH broth was prepared by growing the relevant isolate in CA-MH broth for 48 to 54 h, followed by the removal of cells by centrifugation ($17,000\times g$ for 5 min), filter sterilization (0.22- μ m polyethersulfone [PES] syringe filter; Jet Biofil), and storage at -20°C until required. Cultures of *S. aureus* were exposed to $4\times$ MICs of NP108, and samples were removed hourly for 24 h. Samples were serially diluted in sterile PBS and plated on CA-MH agar plates and incubated for at least 24 h before colonies were enumerated.

Determination of the effect of cationicity on antibacterial activity of NP108. 250 ml flasks of sterile 20 ml CA-MH broth were inoculated with an overnight culture of *S. aureus* SMRSA105 or *S. aureus* EMRSA16 ($\text{OD}_{625} = 0.005$) and incubated at 37°C with shaking (200 rpm) until $\text{OD}_{625} = 0.1$ to 0.3 (logarithmic growth). One half of the flasks were supplemented with PASA, a polyanionic compound used to neutralize the antimicrobial activity of cationic antimicrobial peptides (60), to a final concentration of 2.0% (wt/vol), immediately followed by the addition of 125 mg/liter NP108 ($2\times \text{MIC}_{100}$), 16 mg/liter vancomycin hydrochloride ($2\times \text{MIC}_{100}$), or 4 mg/liter fusidic acid, sodium salt ($2\times \text{MIC}_{100}$) (Discovery Fine Chemicals Ltd., UK) prepared in sterile CA-MH broth to the flasks with and without PASA. The cultures were incubated statically at 37°C, and at each specific time point (15, 30, and 60 min), a 0.02-ml aliquot was removed. Ten-fold serial dilutions to 10^{-7} were prepared in CA-MH broth, and each dilution was spread in triplicate onto CA-MH agar and incubated at 37°C until colonies were observable (~ 24 h) in the untreated inoculated controls. Colonies were counted, and the percentage kill was determined based on the reduction in CFU (CFU/ml) in the treated samples relative to the untreated controls.

Electron microscopy to determine the effect of NP108 on the cellular morphology of *S. aureus*. Flasks (250 ml) containing 20 ml sterile CA-MH broth were inoculated with an overnight culture of *S. aureus* SMRSA105 (optical density at 625 nm [OD_{625}] = 0.005) and incubated at 37°C with shaking (200 rpm) until an OD_{625} of 0.1 to 0.3 was achieved (logarithmic growth). Bacteria (500 μ l from 10 ml for SEM) were added to an equal volume of CA-MH broth with 125 mg/liter NP108 ($2\times \text{MIC}_{100}$). NP108 and bacteria were incubated statically at 37°C for 30 min or 60 min followed by the addition of 2% (wt/vol) PASA and centrifugation (10 min at $13,000\times g$). The cell pellets were resuspended and fixed in 1 ml 5% (wt/vol) glutaraldehyde in 0.2 M sodium phosphate buffer (pH 7.2) and were stored at 4°C. For SEM, cells were processed using a series of ethanol and hexamethyldisilazane dehydration procedures before gold mounting. For TEM, cells were dehydrated through a series of ethanol and acetone steps before being embedded in wax resin, stained with uranyl-acetate lead citrate to improve contrast, sectioned at 90 nm, and mounted onto copper grids. TEM and SEM micrographs were taken on a JEM-1400 Plus JEOL transmission electron microscope and a Zeiss EVO MA10 scanning electron microscope, respectively.

Formulation of NP108 into aqueous hydrogels and antimicrobial susceptibility testing. Sterile (autoclaved at 121°C for 20 min) water-soluble formulations containing NP108 were prepared. NP108 was aseptically added to all formulations at a concentration of 2.0% (wt/vol). Formulations without NP108 served as vehicle controls, and Bactroban nasal ointment (2.0% [wt/wt] mupirocin calcium) was used as an antibiotic kill control.

Antimicrobial susceptibility testing was carried out using *S. aureus* ATCC 25923 grown overnight on CA-MH agar plates at 37°C. The culture was diluted to the 0.5 McFarland standard in sterile PBS ($\sim 10^8$ CFU/ml), spread plated on the surface of CA-MH plates made with 1.5% (wt/vol) ultra-high-resolution agarose (Melford Laboratories Ltd., UK) in place of agar to reduce electrostatic interactions that occur with the negatively charged sulfate and sugar components of the agarose in agar (61), and allowed to dry for 10 min at room temperature. Aliquots (0.2 ml) of formulations containing NP108 and formulation only controls were placed in the center of the lawn of *S. aureus* ATCC 25923 and incubated for 16 to 18 h at 37°C. Antimicrobial efficacy was demonstrated by a zone of no bacterial growth around the site of application of the formulation or Bactroban nasal ointment.

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <https://doi.org/10.1128/AAC.00502-17>.

SUPPLEMENTAL FILE 1, PDF file, 0.2 MB.

ACKNOWLEDGMENTS

D.K.M., L.K.K., D.W.S., J.R., and D.A.O. are employees of NovaBiotics Ltd. D.A.O. is a director and shareholder of NovaBiotics Ltd.

D.K.M., L.K.K., F.H., D.W.S., and J.R. carried out the experiments described in the manuscript. D.K.M., L.K.K., and D.A.O. came up with the ideas and designed the experiments conducted in the manuscript. D.K.M., D.A.O., and L.K.K. wrote and edited the manuscript. Samples for electron microscopy were prepared by the microscopy and histology facility at the University of Aberdeen.

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

REFERENCES

- Kong EF, Johnson JK, Jabra-Rizk MA. 2016. Community-associated methicillin-resistant *Staphylococcus aureus*: an Enemy amidst Us. *PLoS Pathog* 12:e1005837. <https://doi.org/10.1371/journal.ppat.1005837>.
- Monaco M, Pimentel de Araujo F, Cruciani M, Coccia EM, Pantosti A. 5 March 2016. Worldwide epidemiology and antibiotic resistance of *Staphylococcus aureus*. *Curr Top Microbiol Immunol* https://doi.org/10.1007/82_2016_3.
- Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG, Jr. 2015. *Staphylococcus aureus* infections: epidemiology, pathophysiology, clinical manifestations, and management. *Clin Microbiol Rev* 28:603–661. <https://doi.org/10.1128/CMR.00134-14>.
- Stryjowski ME, Corey GR. 2014. Methicillin-resistant *Staphylococcus aureus*: an evolving pathogen. *Clin Infect Dis* 58 Suppl 1:S10–S19. <https://doi.org/10.1093/cid/cit613>.
- Purrello SM, Garau J, Giamarellos E, Mazzei T, Pea F, Soriano A, Stefani S. 2016. Methicillin-resistant *Staphylococcus aureus* infections: a review of the currently available treatment options. *J Glob Antimicrob Resist* 7:178–186. <https://doi.org/10.1016/j.jgar.2016.07.010>.
- European Centre for Disease Prevention and Control. 2016. Summary of the latest data on antibiotic resistance in the European Union. European Centre for Disease Prevention and Control, Stockholm, Sweden.
- Peterson LR, Schora DM. 2016. Methicillin-resistant *Staphylococcus aureus* control in the 21st century: laboratory involvement affecting disease impact and economic benefit from large population studies. *J Clin Microbiol* 54:2647–2654. <https://doi.org/10.1128/JCM.00698-16>.
- Chaves-Moreno D, Wos-Oxley ML, Jauregui R, Medina E, Oxley AP, Pieper DH. 2016. Exploring the transcriptome of *Staphylococcus aureus* in its natural niche. *Sci Rep* 6:33174. <https://doi.org/10.1038/srep33174>.
- Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, Nouwen JL. 2005. The role of nasal carriage in *Staphylococcus aureus* infections. *Lancet Infect Dis* 5:751–762. [https://doi.org/10.1016/S1473-3099\(05\)70295-4](https://doi.org/10.1016/S1473-3099(05)70295-4).
- Price JR, Cole K, Bexley A, Kostiou V, Eyre DW, Golubchik T, Wilson DJ, Crook DW, Walker AS, Peto TE, Llewelyn MJ, Paul J, Modernising Medical Microbiology informatics g. 2016. Transmission of *Staphylococcus aureus* between health-care workers, the environment, and patients in an intensive care unit: a longitudinal cohort study based on whole-genome sequencing. *Lancet Infect Dis* 17:207–214. [https://doi.org/10.1016/S1473-3099\(16\)30413-3](https://doi.org/10.1016/S1473-3099(16)30413-3).
- van Belkum A. 2016. Hidden *Staphylococcus aureus* carriage: overrated or underappreciated? *mBio* 7:e00079-16. <https://doi.org/10.1128/mBio.00079-16>.
- Verhoeven PO, Gagnaire J, Botelho-Nevers E, Grattard F, Carricajo A, Lucht F, Pozzetto B, Berthelot P. 2014. Detection and clinical relevance of *Staphylococcus aureus* nasal carriage: an update. *Expert Rev Anti Infect Ther* 12:75–89. <https://doi.org/10.1586/14787210.2014.859985>.
- Allegranzi B, Bischoff P, de Jonge S, Kubilay NZ, Zayed B, Gomes SM, Abbas M, Atema JJ, Gans S, van Rijen M, Boermeester MA, Egger M, Kluytmans J, Pittet D, Solomkin JS, WHO Guidelines Development Group. 2016. New WHO recommendations on preoperative measures for surgical site infection prevention: an evidence-based global perspective. *Lancet Infect Dis* 16:e276–e287. [https://doi.org/10.1016/S1473-3099\(16\)30398-X](https://doi.org/10.1016/S1473-3099(16)30398-X).
- Allegranzi B, Zayed B, Bischoff P, Kubilay NZ, de Jonge S, de Vries F, Gomes SM, Gans S, Wallert ED, Wu X, Abbas M, Boermeester MA, Dellinger EP, Egger M, Gastmeier P, Guirao X, Ren J, Pittet D, Solomkin JS, WHO Guidelines Development Group. 2016. New WHO recommendations on intraoperative and postoperative measures for surgical site infection prevention: an evidence-based global perspective. *Lancet Infect Dis* 16:e288–e303. [https://doi.org/10.1016/S1473-3099\(16\)30402-9](https://doi.org/10.1016/S1473-3099(16)30402-9).
- Cho OH, Baek EH, Bak MH, Suh YS, Park KH, Kim S, Bae IG, Lee SH. 2016. The effect of targeted decolonization on methicillin-resistant *Staphylococcus aureus* colonization or infection in a surgical intensive care unit. *Am J Infect Control* 44:533–538. <https://doi.org/10.1016/j.ajic.2015.12.007>.
- Poovelikunnel T, Gethin G, Humphreys H. 2015. Mupirocin resistance: clinical implications and potential alternatives for the eradication of MRSA. *J Antimicrob Chemother* 70:2681–2692. <https://doi.org/10.1093/jac/dkv169>.
- Harbarth S, Liassine N, Dharan S, Herrault P, Auckenthaler R, Pittet D. 2000. Risk factors for persistent carriage of methicillin-resistant *Staphylococcus aureus*. *Clin Infect Dis* 31:1380–1385. <https://doi.org/10.1086/317484>.
- Hetem DJ, Bootsma MC, Bonten MJ. 2016. Prevention of surgical site infections: decontamination with mupirocin based on preoperative screening for *Staphylococcus aureus* carriers or universal decontamination? *Clin Infect Dis* 62:631–636. <https://doi.org/10.1093/cid/civ990>.
- Humphreys H, Becker K, Dohmen PM, Petrosillo N, Spencer M, van Rijen M, Wechsler-Fordos A, Pujol M, Duboux A, Garau J. 2016. *Staphylococcus aureus* and surgical site infections: benefits of screening and decolonization before surgery. *J Hosp Infect* 94:295–304. <https://doi.org/10.1016/j.jhin.2016.06.011>.
- Lee AS, Macedo-Vinas M, Francois P, Renzi G, Schrenzel J, Vernaz N, Pittet D, Harbarth S. 2011. Impact of combined low-level mupirocin and genotypic chlorhexidine resistance on persistent methicillin-resistant *Staphylococcus aureus* carriage after decolonization therapy: a case-control study. *Clin Infect Dis* 52:1422–1430. <https://doi.org/10.1093/cid/cir233>.
- Walker ES, Vasquez JE, Dula R, Bullock H, Sarubbi FA. 2003. Mupirocin-resistant, methicillin-resistant *Staphylococcus aureus*: does mupirocin remain effective? *Infect Control Hosp Epidemiol* 24:342–346. <https://doi.org/10.1086/502218>.
- Kampf G. 2016. Acquired resistance to chlorhexidine - is it time to establish an 'antiseptic stewardship' initiative? *J Hosp Infect* 94:213–227. <https://doi.org/10.1016/j.jhin.2016.08.018>.
- da Cunha NB, Cobacho NB, Viana JF, Lima LA, Sampaio KB, Dohms SS, Ferreira AC, de la Fuente-Nunez C, Costa FF, Franco OL, Dias SC. 2017. The next generation of antimicrobial peptides (AMPs) as molecular therapeutic tools for the treatment of diseases with social and economic impacts. *Drug Discov Today* 22:234–248. <https://doi.org/10.1016/j.drudis.2016.10.017>.
- Lee TH, Hall KN, Aguilar MI. 2016. Antimicrobial peptide structure and mechanism of action: a focus on the role of membrane structure. *Curr Top Med Chem* 16:25–39. <https://doi.org/10.2174/1568026615666150703121700>.
- Lohner K. 2017. Membrane-active antimicrobial peptides as template structures for novel antibiotic agents. *Curr Top Med Chem* 17:508–519. <https://doi.org/10.2174/1568026616666160713122404>.
- Zaslouff M. 2002. Antimicrobial peptides of multicellular organisms. *Nature* 415:389–395. <https://doi.org/10.1038/415389a>.
- Brogden KA. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? *Nat Rev Microbiol* 3:238–250. <https://doi.org/10.1038/nrmicro1098>.

28. Chan DJ, Prenner EJ, Vogel HJ. 2006. Tryptophan- and arginine-rich antimicrobial peptides: structures and mechanisms of action. *Biochim Biophys Acta* 1758:1184–1202. <https://doi.org/10.1016/j.bbame.2006.04.006>.
29. Matsuzaki K, Nakamura A, Murase O, Sugishita K, Fujii N, Miyajima K. 1997. Modulation of magainin 2-lipid bilayer interactions by peptide charge. *Biochemistry* 36:2104–2111. <https://doi.org/10.1021/bi961870p>.
30. Nguyen LT, Haney EF, Vogel HJ. 2011. The expanding scope of antimicrobial peptide structures and their modes of action. *Trends Biotechnol* 29:464–472. <https://doi.org/10.1016/j.tibtech.2011.05.001>.
31. Hyldgaard M, Mygind T, Vad BS, Stenvang M, Otzen DE, Meyer RL. 2014. The antimicrobial mechanism of action of epsilon-poly-L-lysine. *Appl Environ Microbiol* 80:7758–7770. <https://doi.org/10.1128/AEM.02204-14>.
32. Shima S, Matsuoka H, Iwamoto T, Sakai H. 1984. Antimicrobial action of epsilon-poly-L-lysine. *J Antibiot (Tokyo)* 37:1449–1455. <https://doi.org/10.7164/antibiotics.37.1449>.
33. CLSI. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard—3rd ed. M07-A10. CLSI, Wayne, PA.
34. Casewell MW, Hill RL. 1985. In-vitro activity of mupirocin ('pseudomonic acid') against clinical isolates of *Staphylococcus aureus*. *J Antimicrob Chemother* 15:523–531. <https://doi.org/10.1093/jac/15.5.523>.
35. Hetem DJ, Bonten MJ. 2013. Clinical relevance of mupirocin resistance in *Staphylococcus aureus*. *J Hosp Infect* 85:249–256. <https://doi.org/10.1016/j.jhin.2013.09.006>.
36. Eltringham I. 1997. Mupirocin resistance and methicillin-resistant *Staphylococcus aureus* (MRSA). *J Hosp Infect* 35:1–8. [https://doi.org/10.1016/S0195-6701\(97\)90162-6](https://doi.org/10.1016/S0195-6701(97)90162-6).
37. Lee AS, Gizard Y, Empel J, Bonetti EJ, Harbarth S, Francois P. 2014. Mupirocin-induced mutations in *ileS* in various genetic backgrounds of methicillin-resistant *Staphylococcus aureus*. *J Clin Microbiol* 52:3749–3754. <https://doi.org/10.1128/JCM.01010-14>.
38. Patel JB, Gorwitz RJ, Jernigan JA. 2009. Mupirocin resistance. *Clin Infect Dis* 49:935–941. <https://doi.org/10.1086/605495>.
39. Udo EE, Jacob LE, Mathew B. 2001. Genetic analysis of methicillin-resistant *Staphylococcus aureus* expressing high- and low-level mupirocin resistance. *J Med Microbiol* 50:909–915. <https://doi.org/10.1099/0022-1317-50-10-909>.
40. Proctor RA, von Eiff C, Kahl BC, Becker K, McNamara P, Herrmann M, Peters G. 2006. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. *Nat Rev Microbiol* 4:295–305. <https://doi.org/10.1038/nrmicro1384>.
41. Baumert N, von Eiff C, Schaaff F, Peters G, Proctor RA, Sahl HG. 2002. Physiology and antibiotic susceptibility of *Staphylococcus aureus* small colony variants. *Microb Drug Resist* 8:253–260. <https://doi.org/10.1089/10766290260469507>.
42. Gläser R, Becker K, von Eiff C, Meyer-Hoffert U, Harder J. 2014. Decreased susceptibility of *Staphylococcus aureus* small-colony variants toward human antimicrobial peptides. *J Invest Dermatol* 134:2347–2350. <https://doi.org/10.1038/jid.2014.176>.
43. Koo SP, Bayer AS, Sahl HG, Proctor RA, Yeaman MR. 1996. Staphylocidal action of thrombin-induced platelet microbicidal protein is not solely dependent on transmembrane potential. *Infect Immun* 64:1070–1074.
44. Samuelsen O, Haukland HH, Kahl BC, von Eiff C, Proctor RA, Ulvatne H, Sandvik K, Vorland LH. 2005. *Staphylococcus aureus* small colony variants are resistant to the antimicrobial peptide lactoferricin B. *J Antimicrob Chemother* 56:1126–1129. <https://doi.org/10.1093/jac/dki385>.
45. Sadowska B, Bonar A, von Eiff C, Proctor RA, Chmiela M, Rudnicka W, Rozalska B. 2002. Characteristics of *Staphylococcus aureus*, isolated from airways of cystic fibrosis patients, and their small colony variants. *FEMS Immunol Med Microbiol* 32:191–197. <https://doi.org/10.1111/j.1574-695X.2002.tb00553.x>.
46. Tan NC, Cooksley CM, Roscioli E, Drilling AJ, Douglas R, Wormald PJ, Vreugde S. 2014. Small-colony variants and phenotype switching of intracellular *Staphylococcus aureus* in chronic rhinosinusitis. *Allergy* 69:1364–1371. <https://doi.org/10.1111/all.12457>.
47. von Eiff C, Becker K, Metzke D, Lubritz G, Hockmann J, Schwarz T, Peters G. 2001. Intracellular persistence of *Staphylococcus aureus* small-colony variants within keratinocytes: a cause for antibiotic treatment failure in a patient with Darier's disease. *Clin Infect Dis* 32:1643–1647. <https://doi.org/10.1086/320519>.
48. Chauhan K, Singh P, Kumar V, Shukla PK, Siddiqi MI, Chauhan PM. 2014. Investigation of Ugi-4CC derived 1H-tetrazol-5-yl-(aryl) methyl piperazinyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid: synthesis, biology and 3D-QSAR analysis. *Eur J Med Chem* 78:442–454. <https://doi.org/10.1016/j.ejmech.2014.03.069>.
49. Krismer B, Liebeck M, Janek D, Nega M, Rautenberg M, Hornig G, Unger C, Weidenmaier C, Lalk M, Peschel A. 2014. Nutrient limitation governs *Staphylococcus aureus* metabolism and niche adaptation in the human nose. *PLoS Pathog* 10:e1003862. <https://doi.org/10.1371/journal.ppat.1003862>.
50. Coates A, Hu Y, Bax R, Page C. 2002. The future challenges facing the development of new antimicrobial drugs. *Nat Rev Drug Discov* 1:895–910. <https://doi.org/10.1038/nrd940>.
51. Ooi N, Miller K, Randall C, Rhys-Williams W, Love W, Chopra I. 2010. XF-70 and XF-73, novel antibacterial agents active against slow-growing and non-dividing cultures of *Staphylococcus aureus* including biofilms. *J Antimicrob Chemother* 65:72–78. <https://doi.org/10.1093/jac/dkp409>.
52. Mascio CT, Alder JD, Silverman JA. 2007. Bactericidal action of daptomycin against stationary-phase and nondividing *Staphylococcus aureus* cells. *Antimicrob Agents Chemother* 51:4255–4260. <https://doi.org/10.1128/AAC.00824-07>.
53. Waters EM, Rowe SE, O'Gara JP, Conlon BP. 2016. Convergence of *Staphylococcus aureus* persister and biofilm research: can biofilms be defined as communities of adherent persister cells? *PLoS Pathog* 12:e1006012. <https://doi.org/10.1371/journal.ppat.1006012>.
54. Hamano Y. 2011. Occurrence, biosynthesis, biodegradation, and industrial and medical applications of a naturally occurring epsilon-poly-L-lysine. *Biosci Biotechnol Biochem* 75:1226–1233. <https://doi.org/10.1271/bbb.110201>.
55. Public Health England. 2015. Investigation of nasal samples. SMI B5, Standards for microbiology investigations. Public Health England, London, England.
56. O'Driscoll NH, Labovitiadi O, Cushnie TP, Matthews KH, Mercer DK, Lamb AJ. 2013. Production and evaluation of an antimicrobial peptide-containing wafer formulation for topical application. *Curr Microbiol* 66:271–278. <https://doi.org/10.1007/s00284-012-0268-3>.
57. Hoffman LR, Deziel E, D'Argenio DA, Lepine F, Emerson J, McNamara S, Gibson RL, Ramsey BW, Miller SI. 2006. Selection for *Staphylococcus aureus* small-colony variants due to growth in the presence of *Pseudomonas aeruginosa*. *Proc Natl Acad Sci U S A* 103:19890–19895. <https://doi.org/10.1073/pnas.0606756104>.
58. Cassat JE, Lee CY, Smeltzer MS. 2007. Investigation of biofilm formation in clinical isolates of *Staphylococcus aureus*. *Methods Mol Biol* 391:127–144. https://doi.org/10.1007/978-1-59745-468-1_10.
59. O'Toole GA, Pratt LA, Watnick PI, Newman DK, Weaver VB, Kolter R. 1999. Genetic approaches to study of biofilms. *Methods Enzymol* 310:91–109. [https://doi.org/10.1016/S0076-6879\(99\)10008-9](https://doi.org/10.1016/S0076-6879(99)10008-9).
60. Kwakman PH, te Velde AA, Vandenbroucke-Grauls CM, van Deventer SJ, Zaai SA. 2006. Treatment and prevention of *Staphylococcus epidermidis* experimental biomaterial-associated infection by bactericidal peptide 2. *Antimicrob Agents Chemother* 50:3977–3983. <https://doi.org/10.1128/AAC.00575-06>.
61. Lehrer RI, Rosenman M, Harwig SS, Jackson R, Eisenhauer P. 1991. Ultrasensitive assays for endogenous antimicrobial polypeptides. *J Immunol Methods* 137:167–173. [https://doi.org/10.1016/0022-1759\(91\)90021-7](https://doi.org/10.1016/0022-1759(91)90021-7).



Correction for Mercer et al., “NP108, an Antimicrobial Polymer with Activity against Methicillin- and Mupirocin-Resistant *Staphylococcus aureus*”

Derry K. Mercer,^a Laura K. Katvars,^{a,b} Fiona Hewitt,^a Daniel W. Smith,^a Jennifer Robertson,^a Carol A. Munro,^c Deborah A. O’Neil^a

NovaBiotics Ltd., Craibstone, Aberdeen, United Kingdom^a; University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen, United Kingdom^b; Medical Research Council Centre for Medical Mycology at the University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen, United Kingdom^c

Volume 61, no. 9, e00502-17, 2017, <https://doi.org/10.1128/AAC.00502-17>. Page 1: Carol A. Munro should be added to the list of authors. The updated byline and affiliations are shown above.

Page 11: the last paragraph of Acknowledgments should be replaced with the following sentences. The work of Laura K. Katvars was partly funded by the Biotechnology and Biological Sciences Research Council (BBSRC) (1091582). Carol Munro was supported by the MRC Centre for Medical Mycology (MR/N006364/1).

Citation Mercer DK, Katvars LK, Hewitt F, Smith DW, Robertson J, Munro CA, O’Neil DA. 2018. Correction for Mercer et al., “NP108, an antimicrobial polymer with activity against methicillin- and mupirocin-resistant *Staphylococcus aureus*.” *Antimicrob Agents Chemother* 62:e00114-18. <https://doi.org/10.1128/AAC.00114-18>.

Copyright © 2018 American Society for Microbiology. All Rights Reserved.